Key takeaways
Skyrizi (risankizumab) and Remicade (infliximab) are both medications used to treat autoimmune conditions like Crohn's disease, ulcerative colitis, and psoriatic arthritis. However, they belong to different medication classes. Skyrizi is an interleukin antagonist, while Remicade is a biologic disease-modifying antirheumatic drug (DMARD) that blocks tumor necrosis factor (TNF). Skyrizi is available as an injection that you can administer at home after training, whereas Remicade is given through an intravenous (IV) infusion by a healthcare professional. Skyrizi is typically dosed every 2 to 3 months, depending on the condition, while Remicade is usually given every 6 to 8 weeks. Skyrizi is only available as a brand-name medication, while Remicade has biosimilars like Avsola, Inflectra, and Renflexis. Common side effects of Skyrizi include joint pain and upper respiratory infections, while Remicade can cause nausea, headache, and infusion-related reactions. Both medications can increase the risk of infections, but Remicade also carries risks of serious conditions like cancer and heart problems.
